Transaction overview

MiQ Partners, a US-based intelligent automation firm, acquired CKC Engineering, an Oakland-based precision automation machine building company on December 15, 2021. The deal's value was undisclosed but marked MiQ’s expansion into Northern California and the Pacific Northwest, strengthening its position in the life sciences sector.

Deal structure and financing

Details of the equity split, debt funding, and lead banks involved in the CKC Engineering acquisition by MiQ Partners are not disclosed. Given that the transaction amount is unknown, specific leverage metrics or lock-up terms cannot be determined. The seller retained no stake as part of this 100% acquisition. There were no publicly shared key terms pertaining to IPO optionality.

Strategic context

MiQ Partners sought CKC Engineering to enhance its local service offerings and support for existing clients in Northern California and the Pacific Northwest, alongside increasing capacity to serve additional clients within the life sciences industry. With expertise in automation solutions such as aseptic syringe filling and vertical farming manufacturing, CKC adds complementary skills that bolster MiQ’s ability to deliver comprehensive automation services across multiple sectors.

CKC Engineering was divested by its founders who sought to leverage their company's capabilities within a larger platform like MiQ Partners, ensuring continued growth while tapping into broader market opportunities. The acquisition supports MiQ’s strategic vision of becoming the leading provider of custom automation solutions in manufacturing and aligns with industry trends toward greater demand for specialized equipment and services.

Regulatory path

As a privately held transaction without disclosed financial terms, regulatory scrutiny was likely minimal. No specific jurisdictions or regulators are named as having reviewed this deal; however, given MiQ Partners’ operational footprint spanning multiple states, state-level antitrust authorities may have been involved in preliminary assessments. No remedies were required for the acquisition to proceed.